Rethinking TB testing and treatment in Pediatrics – on demand webinar

Responsive image

Register here to watch the webinar today!

Address1

Dummy field DO NOT USE/ DELETE/ MODIFY Needs to be hidden in CSS on LP

Referral source (URL)*

Script on LP to collect URL

Instrument Type

Buying Type

If Opp Type is INSTRUMENT // For SP creation / could be hidden field

Opportunity Type*

For SP creation / could be hidden field

Interaction Request*

For SP creation / could be hidden field

Lead Source - Most Recent*

For SP creation / could be hidden field

Primary Campaign Source*

For SP creation / could be hidden field

Specific Interest

Dr-Kawaruma-Webinar

Product Line Interest*

For SP creation / could be hidden field

BANT_Budget*

For SP creation / could be hidden field

BANT_Authority*

For SP creation / could be hidden field

BANT_Need*

For SP creation / could be hidden field

BANT_Time*

For SP creation / could be hidden field

First Name*

Last Name*

Company*

Email Address*

Job Position*

Phone*

Country*

State or Province*

What test do you most often use as part of your clinical assessment for diagnosis of LTBI?*

Interferon-gamma release assay (IGRA): QuantiFERON®-TB Gold (Plus)

Interferon-gamma release assay (IGRA): T-SPOT®.TB

Tuberculin Skin Test (TST) / Mantoux

Not applicable

I want to be the first to hear about offers and news from QIAGEN. *

I hereby give QIAGEN the consent to contact me via email and phone (subject to the contact information provided above) with further special offers, contests and product information.

Rethinking TB testing and treatment in Pediatrics – on demand webinar

On June 1st, the American Academy of Pediatrics released the new Red Book® 2018 edition, which expands established AAP recommendations for TB blood testing in children. The AAP now preferentially recommends the use of TB blood tests (IGRAs) in BCG-vaccinated children aged 2 years and older. The new recommendation updates the AAP's previous recommendation for IGRA testing in children starting at age 5. The updated Red Book guidance was driven by data indicating that BCG-vaccinated children testing positive on TST are overtreated for TB infection. More broadly, the AAP states that among immunocompetent children age 2 or older an IGRA may be used in any situation where a TST would historically be used.

Watch our recorded webinar event to learn more about the new AAP guidelines. During this program, you’ll learn more about the rationale behind the new pediatric IGRA recommendations and LTBI treatment regimens, while looking more broadly at how TB elimination efforts are increasingly focused on employing preventive methods in the primary care setting. The program will be led by Dr. Sonia Qasba, a physician at Suburban Hospital, part of Johns Hopkins Medicine. Dr. Qasba is board certified in Infectious Disease, Internal Medicine, and Pediatrics.

1. WHO. Latent tuberculosis infection: Updated and consolidated guidelines for programmatic management. WHO/CDS/TB/2018.4

QuantiFERON-TB Gold Plus (QFT-Plus) is an in vitro diagnostic aid for detection of Mycobacterium tuberculosis infection. QFT-Plus is an indirect test for M. tuberculosis infection (including disease) and is intended for use in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations. QFT-Plus Package Inserts as well as up-to- date licensing information and product-specific disclaimers can be found at www.QuantiFERON.com.

+ Subject to your consent given above, QIAGEN may use your personal information for internal business and marketing purposes. The information will not be sold to any third party. QIAGEN may transfer your personal information to our CRM system (hosted by SalesForce.com, Inc. and Oracle Corp.) solely for the purposes of data hosting and QIAGEN email distribution. You may unsubscribe at any time. Your data will be processed in compliance with applicable privacy laws, including the EU General Data Protection Regulation. For further details, please refer to our Privacy Policy.